News

Sprout pockets $15M for its long-delayed 'female Viagra'

North Carolina's Sprout Pharmaceuticals put together a $15 million funding round, cash the biotech will use to make another go at FDA approval for its female sexual dysfunction treatment.

Pfizer-AstraZeneca sequel could hit theaters next week

Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer  and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.

J&J pours another $20M into ViaCyte and sizes up its diabetes treatment

Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.

Allergan CFO steps down amid buyout drama, but analysts aren't concerned

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Cubist nears another big antibiotic approval as M&A rumors simmer

Lexington, MA's Cubist Pharmaceuticals is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.

Israel's NeuroDerm banks $16M to advance its Parkinson's pump

Israeli biotech NeuroDerm has secured a $16 million investment to support its work on a wearable treatment for Parkinson's disease, working through a mid-stage study on its lead candidate for the neurodegenerative ailment.

AZ may be too expensive for Pfizer, Orexo to up reliance on partners, Santhera raises cash

In this week's EuroBiotech Report, data on the antibiotic AstraZeneca is developing with Actavis' Forest Laboratories and some oncology compounds have burnished AstraZeneca's pipeline, a development that means the Anglo-Swedish drugmaker may now be too expensive to be attractive to Pfizer. And more.

J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test

Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal recipients of their oncology drugs.

Baxter's next hemophilia drug clocks a Phase III success

Baxter's latest hemophilia candidate met its main goals in a late-stage study, clearing the way for an FDA application as the biopharma giant works to expand its cadre of bleeding drugs.

GlaxoSmithKline grabs FDA approval for its latest asthma treatment

GlaxoSmithKline's banner respiratory division picked up another FDA approval, securing the agency's blessing for an inhaled asthma treatment as it expands its stable of drugs for airway disorders.

Eli Lilly joins list of Enbrel-beaters with head-to-head psoriasis showdown

Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer's Enbrel in a head-to-head study. And Lilly says the results are good enough to back a regulatory filing in the first half of 2015 for its IL-17A therapy as it races to gain some new approvals following a punishing onslaught of generic competition to its top drug franchises.

Global fear of Ebola outbreak stokes a frenzy of new R&D, production plans

With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums in Monrovia, the frenzy of attention continued to concentrate a spotlight on the sudden rush to get early-stage experimental treatments or vaccines to West Africa.

NovaBay shares routed after lead program fails another clinical study

About 9 months after NovaBay Pharmaceuticals reported that its lead anti-infective therapy auriclosene had failed a Phase IIb study for impetigo, the little biotech was forced to come back and concede another setback as an opthalmic solution of the same treatment flunked a IIb for viral conjunctivitis, or pink eye, failing the primary and all secondary endpoints.

AstraZeneca's new antibiotic comes through in Phase III

AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot at regulatory approval.

Bristol-Myers, Celgene pair an immuno-oncology star with a rising chemotherapy

Bristol-Myers Squibb and Celgene are joining forces on a cancer combination treatment, testing the former's highly anticipated immunotherapy in tandem with an on-the-market chemo drug against a host of tumor targets.

MorphoSys bets on Emergent BioSolutions' cancer contender in $183M deal

German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.

Could buying Salix get Valeant off of Allergan's scent?

Allergan, working to fend off a hostile approach from Valeant Pharmaceuticals, is reportedly taking a look at the smaller Salix Pharmaceuticals, weighing a multibillion-dollar deal that could render it unattainable--or at least drive up its asking price.

Amicus sets sights on approval as rare disease pill clears Phase III

Amicus Therapeutics has come a long way in two years, shaking off a clinical misstep on the way to a second Phase III success for its rare disease treatment. Now the biotech is preparing to make its case to regulators, hoping to win approval for a new approach to Fabry disease.

Sanofi wins FDA's blessing for an oral Gaucher drug

Sanofi's rare ailment-focused Genzyme unit won FDA approval for a new Gaucher disease treatment, providing an oral alternative to its own trailblazing intravenous therapy.

Sanford-Burnham poaches a GSK exec to bridge academia and Big Pharma

Back in January, the prestigious Sanford-Burnham Medical Research Institute amended its ethos, promising to more closely marry its work to therapeutic development and become a partner of choice for drugmakers. Now, the 38-year-old organization has chosen the leader to get it there, convincing GlaxoSmithKline's Perry Nisen to take the reins as its new CEO.